Tiredwise: the evidence
The tired, complex patient often has more than one thing going on. These conditions cluster, share symptoms and get dismissed as "just anxiety". Here's what the evidence actually says.
Open the Tiredwise workup tool
At a glance
- They cluster. ME/CFS, fibromyalgia, POTS, hypermobility, long COVID, autism and ADHD overlap far more than chance.
- Post-exertional malaise (PEM) is the pivot. It defines ME/CFS, and it changes management: exercise must stay inside the energy envelope.
- Each label has real criteria. Use them. They protect against both dismissal and over-labelling.
- Basic tests first. A short baseline panel catches the treatable mimics (anaemia, thyroid, coeliac, sleep apnoea, depression, medicines).
- MCAS is over-diagnosed. ASCIA requires all three criteria, including objective mediator evidence. POTS or hEDS alone don't count.
- Treatment is mostly symptom-led. Pacing, orthostatic measures, sleep, pain and mood care help. Graded exercise therapy is no longer recommended in ME/CFS.
How they overlap
- ME/CFS and fibromyalgia: about 47% of people with ME/CFS also have fibromyalgia features (meta-analysis, cited in a 2026 review).
- ME/CFS and orthostatic problems: 32.5% of one ME/CFS outpatient cohort (n = 193) had POTS or orthostatic hypotension on tilt testing.
- Long COVID becomes ME/CFS in some people: in RECOVER-Adult (11,785 infected, 1,439 uninfected), 4.5% of infected people met IOM ME/CFS criteria vs 0.6% of uninfected; hazard ratio 4.93.
- Long COVID clinic data: 58% of 247 long COVID patients screened positive for ME/CFS; hypermobility was 27% vs 10% in recovered controls (survey; low response rate).
- Neurodivergence and hypermobility: 50% of neurodivergent adults (n = 109) had generalised joint hypermobility vs 17.5% of controls (OR 4.79). Hypermobility statistically mediated orthostatic symptoms and pain.
- POTS clinics: in one telehealth POTS clinic (n = 277), 39% had ADHD, 9% autism and 78% hypermobility. 70% were "suspected MCAS", but none were lab-confirmed: a warning sign for label creep.
Most overlap data come from specialist clinics and surveys, which over-represent complex cases. Population rates are lower.
The criteria
ME/CFS (IOM 2015)
- All three: a substantial drop in activity for more than 6 months with profound, new fatigue not relieved by rest; post-exertional malaise; unrefreshing sleep.
- Plus one: cognitive impairment or orthostatic intolerance.
- Symptoms present at least half the time, at moderate or worse severity.
- NICE 2021: suspect ME/CFS at 6 weeks in adults (4 weeks in children) and give interim energy advice; diagnose at 3 months.
Fibromyalgia (ACR 2016)
- Widespread Pain Index (WPI, 0–19) ≥7 and Symptom Severity Scale (SSS, 0–12) ≥5, or WPI 4–6 and SSS ≥9.
- Generalised pain in at least 4 of 5 regions (jaw, chest and abdomen don't count towards regions).
- Symptoms for at least 3 months. The diagnosis stands regardless of other diagnoses.
POTS (HRS 2015)
- Sustained heart rate rise ≥30 bpm (≥40 bpm aged 12–19) within 10 minutes of standing or tilt.
- No orthostatic hypotension (systolic drop ≥20 or diastolic drop ≥10 mmHg).
- Symptoms of orthostatic intolerance for at least 3 months, and no other cause (dehydration, bleeding, medicines, deconditioning, thyroid).
- In general practice, a 10-minute active stand or passive lean (NASA lean) test is usually enough to start.
Hypermobility (2017 EDS classification)
- Beighton score (0–9): ≥6 before puberty, ≥5 from puberty to 50, ≥4 over 50.
- hEDS needs all three 2017 criteria (joint hypermobility, systemic or family features, and exclusions). It has no genetic test.
- Most symptomatic hypermobile people have hypermobility spectrum disorder (HSD), which is managed the same way.
MCAS (ASCIA 2025)
- All three: typical episodic symptoms in at least 2 organ systems; objective mediator release; response to mediator-blocking treatment.
- Tryptase is the marker of choice: an acute level ≥ 20% of baseline + 2 ng/mL, taken 30 minutes to 2 hours after an episode, with a baseline at least 24 hours after it settles.
- Urinary or blood histamine aren't recommended (poor accuracy). Prostaglandin D2 and leukotriene E4 tests aren't validated or offered in Australia.
- ASCIA: there's no scientific evidence linking hEDS or POTS to mast cell dysregulation, and these shouldn't be used as criteria. MCAS is a diagnosis of exclusion.
Long COVID (NASEM 2024)
- A chronic condition after SARS-CoV-2 infection, lasting at least 3 months, continuous, relapsing or progressive, affecting one or more organ systems.
- No positive test is needed. Infection can be confirmed, probable or possible.
Autism and ADHD in adults
- Both are lifelong. Ask about childhood, school, sensory load, masking and burnout.
- Screens: ASRS v1.1 (ADHD) and AQ-10 (autism). A positive screen means referral or fuller assessment, not a diagnosis.
- "Autistic burnout" is widely described by autistic adults, but research is still mainly qualitative.
Workup: what to test
- NICE baseline: urinalysis, FBC, UEC, LFTs, TFTs, ESR or CRP, calcium and phosphate, HbA1c, ferritin, coeliac serology, CK.
- Often worth adding: B12 and folate, vitamin D, pregnancy test, ECG if palpitations or syncope, morning cortisol if low sodium, low BP or pigmentation, HIV and hepatitis serology by risk.
- At the bedside: lying and standing obs (10-minute stand), Beighton score, sleep apnoea screen (STOP-BANG), PHQ-9 and GAD-7, medicine and substance review.
- Usually not useful: repeated viral serology without a clinical reason, urinary histamine, "adrenal fatigue" or salivary cortisol panels, IgG food intolerance tests, routine genetic tests for hEDS, mould or "biotoxin" panels.
What helps
Good trials or guideline support · Some limited or mixed · Expert consensus only · Avoid harm or no benefit
Everyone
- Expert Believe and validate. Name what you find. Document function, not just symptoms.
- Expert Pacing and energy management (NICE 2021). Heart rate or activity tracking can help some people stay inside their envelope.
- Avoid Graded exercise therapy with fixed increments in ME/CFS (NICE 2021). CBT can support coping but isn't a cure.
- Some Treat sleep problems: CBT for insomnia, sleep apnoea treatment, and circadian advice for delayed sleep (common in ADHD).
- Good Treat co-existing depression and anxiety. They're common companions, not an alternative explanation.
POTS and orthostatic intolerance
- Expert 2–3 L fluid a day and more salt (HRS 2015 suggests 10–12 g salt), if there's no reason not to.
- Some Waist-high compression or an abdominal binder; counter-manoeuvres when standing.
- Some Recumbent exercise (rowing, recumbent bike, swimming) built up slowly. In PEM, keep within the envelope.
- Some Low-dose propranolol (10–20 mg) improved symptoms more than 80 mg in a crossover trial. Ivabradine, fludrocortisone and midodrine are off-label options, often with specialist input.
Fibromyalgia
- Good Exercise is the only "strong for" EULAR recommendation. In PEM, start very low and progress only if there's no crash.
- Some Psychological therapies, mindfulness, tai chi, yoga and hydrotherapy (weak for).
- Some Low-dose amitriptyline, duloxetine or pregabalin for severe pain or sleep problems (weak for; modest effects).
- Avoid Strong opioids and corticosteroids.
Hypermobility
- Some Physio for strength, proprioception and joint control; OT for joint protection and pacing.
- Expert Refer to genetics only if there are features of another connective tissue disorder (for example vascular EDS or Marfan features).
MCAS (when criteria are met)
- Expert Avoid triggers. Trial non-sedating H1 antihistamines, then add an H2 antihistamine, montelukast or a mast cell stabiliser, with specialist guidance.
- Avoid Restrictive "low histamine" diets: there's no evidence base (ASCIA).
Long COVID
- Expert No proven disease-modifying treatment yet. Treat the components (PEM, orthostatic intolerance, sleep, mood, breathlessness) and screen for ME/CFS.
- Some Low-dose naltrexone and other repurposed drugs: early and mixed data. Use within trials or with specialist input.
Autism and ADHD
- Good Treating ADHD improves function. Stimulants raise heart rate, so monitor in POTS.
- Expert Autism: reduce sensory and social load, allow recovery time, and offer reasonable adjustments at work or study.
Gaps and honest uncertainty
- No biomarker yet for ME/CFS, fibromyalgia or long COVID.
- Most overlap figures come from specialist clinics, not the community.
- Whether hypermobility causes dysautonomia, or they share a cause, is unknown.
- MCAS is both over-labelled and, when real, under-tested. Proper tryptase timing is rarely done.
- Australia's NHMRC ME/CFS guideline is still in development. Check the NHMRC page for its status.
Sources
- Institute of Medicine. Beyond ME/CFS: redefining an illness (2015)
- NICE NG206. ME/CFS: diagnosis and management (2021)
- NHMRC. ME/CFS guideline development (in progress)
- Wolfe F et al. 2016 revisions to the fibromyalgia diagnostic criteria. Semin Arthritis Rheum 2016
- Macfarlane GJ et al. EULAR revised recommendations for fibromyalgia. Ann Rheum Dis 2017
- Sheldon RS et al. 2015 HRS consensus on POTS. Heart Rhythm 2015
- Raj SR et al. Low-dose propranolol in POTS: less is more. Circulation 2009
- Malfait F et al. 2017 international classification of the Ehlers–Danlos syndromes. Am J Med Genet C 2017
- ASCIA. Mast cell disorders, health professional information (2025)
- NASEM 2024 long COVID definition (summary)
- RECOVER-Adult: post-COVID ME/CFS incidence
- Csecs JLL et al. Joint hypermobility links neurodivergence to dysautonomia and pain. Front Psychiatry 2022
- Grach SL et al. Long COVID overlap with ME/CFS, hypermobility and POTS. Front Neurol 2024
- Ganesh R et al. Overlap of hypermobility, POTS, MCAS and ME/CFS (review), 2024
- POTS clinic cohort: ADHD, autism and suspected MCAS (J Clin Med 2026)
- ME/CFS and fibromyalgia overlap review (J Transl Med 2026)